Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Abbott recalls some FreeStyle Libre 3 sensors due to incorrect glucose readings, risking severe health issues.
Designed for people interested in improving their overall health and wellnessProvides real-time glucose data and personal coach...
The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant dep...
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Qu...
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a ...
- Press Conference
Citigroup analyst Joanna Wiensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises the price target from $119 t...
